PET Agent Gets FDA Fast Track Designation for Cardiac AL and ATTR Amyloidosis
Previously approved for the detection of neuritic beta amyloid plaque, the PET agent (18F)florbetaben is currently being evaluated in a phase 3 multicenter trial for the diagnosis of cardiac amyloidosis.
The Food and Drug Administration (FDA) has granted fast track designation for potential use of the positron emission tomography (PET) agent 18F(florbetaben) in the detection of cardiac amyloid light-chain (AL) and amyloid transthyretin-related (ATTR) amyloidosis.
Currently indicated for the estimation of beta amyloid neuritic plaque density on PET scans for patients being assessed for cognitive decline, 18F(florbetaben) (Neuraceq, Life Molecular Imaging) is currently the subject of a phase 3 multicenter trial for detection of cardiac amyloidosis, according to Life Molecular Imaging.
The positron emission tomography (PET) agent 18F(florbetaben) (Neuraceq, Life Molecular Imaging) is currently being evaluated in a phase 3 multicenter trial for detection of cardiac amyloidosis. The radiopharmaceutical 18F(florbetaben) was recently granted with the fast track designation by the FDA for the detection of cardiac amyloid light-chain (AL) and amyloid transthyretin-related (ATTR) amyloidosis. (Images courtesy of the Journal of Nuclear Medicine.)
“Diagnosing cardiac AL amyloidosis is complex and challenging,” added Andrew Stephens, MD, PhD, CMO of Life Molecular Imaging. “(18F)florbetaben PET imaging of patients with suspected cardiac amyloidosis has the potential to streamline the diagnostic process, providing earlier and appropriate access to therapy and improved monitoring of such interventions.”
Noting the safety profile of the radiopharmaceutical, Life Molecular Imaging said clinical trial research involving nearly 1,100 administrations of 18F(florbetaben) revealed that the most common adverse drug reactions were injection site pain in 3.4 percent of patients and injection site erythema in 1.7 percent of patients.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can CT-Based AI Help Predict Renal Function Decline After Radioligand Therapy for mCRPC?
February 25th 2025In patients who had at least four cycles of 177Lu-PSMA-I&T for mCRPC, new research shows that a 10 percent or greater decrease in total kidney volume on CT at six months has a 90 percent AUC for predicting estimated glomerular filtration rates (eGFRs) of 30 percent or greater at one year.
